InfectoGnostics Research Campus Jena receives 8 million euros for third funding phase
The InfectoGnostics Research Campus Jena has secured almost 8 million euros for seven new projects in the third and final phase of the funding initiative of the Federal Ministry of Research, Technology and Space (BMFTR). Starting in October 2025, the campus will be funded for four years as part of the “Research Campus – Public-Private Partnership for Innovation” initiative. The jury of experts praised the strategic development and the contribution of the campus to the clinical implementation of innovative diagnostic solutions.

For more than eleven years, InfectoGnostics has been bringing together partners from science, industry and clinical practice to diagnose infectious diseases more quickly and detect antibiotic resistance at an early stage. The new projects target rapid molecular tests for care facilities, quantitative home tests for inflammatory markers, pathogen diagnostics from cell-free DNA, an automated multiparameter analyzer and a Raman-based system for T cell characterization. In addition, organ-on-chip platforms are being developed to test the efficacy of substances against bacterial pathogens. A general practitioner transfer project supports the practical implementation.
The second funding phase until September 2025 laid the foundation through open technology platforms and the involvement of end users. Developments such as digital PCR, rapid tests and wastewater monitoring have been tested in clinical trials or further developed into marketable products. About half of the budget is financed by the partners, and the Free State of Thuringia also supports the innovation cluster.
Read Also:
Tumor-on-chip model revolutionizes CAR-T cell therapy – MedLabPortal
Editor: X-Press Journalistenbüro GbR
Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.